Oculis Reveals Breakthrough Findings on Privosegtor Therapy
Oculis Unveils Positive Phase 2 Trial Results for Privosegtor
Exciting news has emerged from Oculis Holding AG, a forward-thinking biopharmaceutical company specializing in treatments for ophthalmic and neuro-ophthalmic conditions. The company recently announced that it will present results from its Phase 2 ACUITY trial, which investigates Privosegtor (OCS-05) in treating acute optic neuritis, during the upcoming European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress.
Presentation Details at ECTRIMS 2025
At ECTRIMS, Oculis will highlight groundbreaking data demonstrating the efficacy of Privosegtor in a multicenter, randomized, placebo-controlled trial. The presentation, titled Reduction in Retinal Ganglion Cell Loss and Improved Low Contrast Visual Acuity with Privosegtor in Acute Optic Neuritis: Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial, is set for Wednesday, September 24, 2025, at 08:30 CET and will be delivered by Dr. Céline Louapre from Pitié-Salpêtrière Hospital.
Significance of the Findings
Dr. Riad Sherif, Chief Executive Officer of Oculis, expressed enthusiasm about the collaboration with Pitié-Salpêtrière Hospital. He shared, "Our Phase 2 ACUITY trial demonstrated clinically meaningful improvements in vision, with patients experiencing an average increase of 18 letters in vision over three months. The preservation of retinal structure and the favorable safety profile are very encouraging, suggesting that Privosegtor may have significant applicability in various neurological conditions.”
Dr. Louapre added her insights, stating, "Presenting at ECTRIMS is an honor, as it is one of the largest MS congresses worldwide. The results underline the possibility for Privosegtor (OCS-05) to have a transformative impact on patients suffering from acute relapses of multiple sclerosis, particularly since acute optic neuritis can frequently be the initial sign of this debilitating disease."
About Privosegtor (OCS-05)
Privosegtor is an innovative peptoid small molecule candidate focusing on neuroprotection for patients suffering from acute optic neuritis and other associated conditions. In the Phase 2 ACUITY trial, Privosegtor demonstrated not only anatomical preservation of retinal structures but also improvements in visual acuity. Animal studies mirrored these findings, with significant protection against retinal ganglion cell damage and enhancements in clinical functions.
This investigational drug has received orphan drug designations from both the FDA and EMA, highlighting its potential in treating acute optic neuritis. The implications for a neuroprotective treatment extend into numerous neuro-ophthalmic and neurological areas, underscoring the broad potential of this candidate.
Understanding Acute Optic Neuritis
Acute optic neuritis, a rare but serious condition, involves inflammation of the optic nerve that can lead to significant visual impairment. It predominantly affects individuals between the ages of 20 and 40 and occurs more often in women. Symptoms typically begin with ocular pain and subsequent vision loss which, if untreated, can lead to lasting damage due to the fragility of unprotected neurons.
About Oculis
Oculis is at the forefront of innovation in biopharmaceuticals, dedicated to addressing the growing needs in the fields of ophthalmology and neurology. With a pipeline that includes OCS-01, an eye drop aimed at diabetic macular edema; Privosegtor (OCS-05); and Licaminlimab (OCS-02), a topical treatment currently in Phase 2, the company exemplifies a commitment to pioneering research to enhance treatment options for patients. Headquartered in Switzerland, Oculis operates with a strong team experienced in delivering successful therapeutic solutions.
If you wish to know more about Oculis or its groundbreaking research, you can reach out through their corporate communications channels.
Frequently Asked Questions
What is the Phase 2 ACUITY trial?
The Phase 2 ACUITY trial investigates the efficacy of Privosegtor (OCS-05) in patients suffering from acute optic neuritis, focusing on visual function and retinal preservation.
Who presented the findings at ECTRIMS?
Dr. Céline Louapre from Pitié-Salpêtrière Hospital is set to present these findings at the ECTRIMS congress.
What were the main results of the trial?
The trial demonstrated a noteworthy improvement in vision with an average gain of 18 letters at the three-month mark, alongside enhanced retinal health.
What is the significance of Privosegtor?
Privosegtor is seen as a promising neuroprotective therapy, not only for acute optic neuritis but potentially for broader neurological applications.
What is Oculis' mission?
Oculis aims to innovate and provide solutions for ophthalmic and neuro-ophthalmic diseases, addressing significant unmet medical needs through their diverse product pipeline.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
